Research Topic: clinical outcomes

Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response

mycolabadmin

Researchers studied how LSD and psilocybin work in real-world therapy settings in Switzerland. They found that these compounds effectively reduced depression symptoms in patients who hadn’t responded to other treatments. Surprisingly, the feeling of relaxation during the session was more important for improvement than having intense mystical experiences. The therapy was generally safe, with side effects that resolved quickly.

Read More »

Body mass index (BMI) does not predict responses to psilocybin

mycolabadmin

Researchers investigated whether a person’s body weight affects how they respond to psilocybin-assisted therapy. Analyzing 77 participants across three studies, they found that BMI did not predict how intensely people experienced the drug or how much their mental health improved afterward. This surprising finding suggests that everyone might benefit from the same fixed dose of psilocybin rather than doses adjusted to body weight, making therapy simpler and more cost-effective to deliver at scale.

Read More »

Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use

mycolabadmin

Researchers followed 654 people planning to use psychedelics and measured their thinking patterns before and after. They found that delusional thinking actually decreased after use, while about one-third experienced visual effects like seeing trails or intensified colors. However, very few people (less than 1%) found these visual effects bothersome. Younger people, women, and those with psychiatric history were more likely to experience these visual effects.

Read More »

The Rising Threat of Mucormycosis: Oman’s Experience Before and During the COVID-19 Pandemic

mycolabadmin

Mucormycosis is a serious fungal infection that became much more common in Oman during the COVID-19 pandemic. Most patients had diabetes and nearly half had COVID-19, with very high death rates. The infection primarily affects the sinuses and brain, and requires aggressive treatment with surgery and antifungal medications. This study shows doctors need better tools to detect and treat this dangerous infection, especially during health crises.

Read More »

Efficacy of Topical Antifungal Nail Solution Versus Topical Placebo Solution for the Treatment of Pedal Onychomycosis: A Randomized Controlled Trial

mycolabadmin

This study tested whether a new antifungal solution called Tolcylen® could effectively treat toenail fungus compared to a placebo. Over 9 months, participants using the active treatment showed dramatic improvements, with over half achieving complete fungal elimination and 70% showing significant nail healing. Beyond just getting rid of the fungus, patients reported much better quality of life with less discomfort and improved appearance as early as 3 months into treatment.

Read More »

Clinical Outcomes of Micafungin for Invasive Fungal Infections in the Obese and Nonobese

mycolabadmin

This study examined whether obese patients treated with the antifungal drug micafungin for serious fungal infections had different outcomes compared to non-obese patients. Researchers reviewed 378 patient cases and found that both groups had similar success rates of about 50%, suggesting that the standard dose of micafungin works equally well in obese and non-obese patients. These findings suggest that doctors do not need to prescribe higher doses of micafungin specifically for obese patients, though more research is needed to fully understand how obesity affects antifungal treatment.

Read More »
Scroll to Top